A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05259722 |
|
Recruitment Status :
Completed
First Posted : February 28, 2022
Last Update Posted : April 9, 2024
|
Sponsor:
LEO Pharma
Information provided by (Responsible Party):
LEO Pharma
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable. Eligible participants will be randomised to receive topical administration of delgocitinib cream 20 mg/g, twice-daily, or oral administration of alitretinoin capsules 30 mg (with an option to reduce to 10 mg during trial conduct), once-daily. The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life.
The purpose of this trial is to compare the efficacy, health-related quality of life, and safety of delgocitinib cream and alitretinoin capsules.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Hand Eczema | Drug: Delgocitinib Drug: Toctino | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 513 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A 24 Week, Randomised, Assessor Blinded, Active-controlled, Parallel Group, Phase 3, 2 Arm Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema |
| Actual Study Start Date : | June 15, 2022 |
| Actual Primary Completion Date : | November 8, 2023 |
| Actual Study Completion Date : | December 5, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Atopic dermatitis
MedlinePlus related topics:
Eczema
Drug Information
available for:
Alitretinoin
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Delgocitinib cream 20 mg/g
Twice-daily topical application for up to 24 weeks
|
Drug: Delgocitinib
Cream for topical application 20 mg/g |
|
Active Comparator: Alitretinoin capsules 30 mg per capsule
1 capsule per day for up to 24 weeks
|
Drug: Toctino
1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur |
Primary Outcome Measures :
- Change in HECSI score from baseline to Week 12 [ Time Frame: 12 weeks ]The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).
Secondary Outcome Measures :
- HECSI-90 at Week 12 [ Time Frame: 12 weeks ]The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.
- IGA-CHE TS at Week 12. [ Time Frame: 12 weeks ]The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.
- Change in HESD itch score (weekly average) from baseline to Week 12 [ Time Frame: 12 weeks ]The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.
- Change in HESD pain score (weekly average) from baseline to Week 12. [ Time Frame: 12 weeks ]The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.
- AUC of HECSI-90 from baseline up to Week 24 [ Time Frame: 24 weeks ]The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. The area under the curve (AUC) at participant level will be determined as follows: 1 will be assigned when response is observed and 0 otherwise. The AUC is interpreted as number of days with 90% reduction in HECSI score until Week 24.
- AUC of change from baseline in DLQI score up to Week 24 [ Time Frame: 24 weeks ]The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30). The area under the curve (AUC) at patient level will be determined from the change from baseline in DLQI score estimated piecewise from Week 0 to Week 24. Differences will be analysed with opposite sign to interpret positive area as improvement in scores and negative area as worsening.
- Change in HECSI score from baseline to Week 24 [ Time Frame: 24 weeks ]The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).
- Number of treatment-emergent AEs from baseline up to Week 26 [ Time Frame: 26 weeks ]An adverse event (AE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.
- Number of treatment-emergent SAEs from baseline up to Week 26 [ Time Frame: 26 weeks ]A serious adverse event (SAE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.
- Number of AEs leading to IMP discontinuation up to Week 24 [ Time Frame: 24 weeks ]The investigational medicinal product (IMP) will be discontinued permanently in case of an AE that, in the opinion of the investigator or sponsor's medical expert, contraindicates further dosing. The investigator will assess the relationship between investigational medicinal product (IMP) and the adverse event (AE).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Main inclusion criteria:
- Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
- Disease severity graded as severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 4).
- Participants who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
- Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.
- Participants must use contraceptive methods in accordance with local regulations regarding the methods of contraception for those participating in clinical studies
Main exclusion criteria:
- Concurrent skin diseases on the hands, e.g. tinea manuum.
- Active atopic dermatitis requiring medical treatment in regions other than the hands and feet.
- Active psoriasis on any part of the body.
- Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
- Clinically significant infection on the hands.
- Participants who cannot receive alitretinoin.
- Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial.
- History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
-
Any disorder which is not stable and could:
- Affect the safety of the participant throughout the trial.
- Impede the participant's ability to complete the trial.
- Positive hepatitis B surface antigen or hepatitis C virus antibody serology at screening.
- Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline.
- Use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline.
- Previous or current treatment with Janus kinase (JAK) inhibitors (including delgocitinib/LEO 124249), systemic or topical.
- Cutaneously applied treatment with immunomodulators or TCS on the hands within 14 days prior to baseline.
- Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
- Other transdermal or cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 7 days prior to baseline.
- Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
-
Treatment with any marketed biological therapy or investigational biologic agents:
- Any cell-depleting agents: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
- Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
- Previously used alitretinoin or participated in a clinical trial with alitretinoin or delgocitinib.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05259722
Locations
Show 102 study locations
Sponsors and Collaborators
LEO Pharma
Investigators
| Study Director: | Medical Expert | LEO Pharma |
| Responsible Party: | LEO Pharma |
| ClinicalTrials.gov Identifier: | NCT05259722 |
| Other Study ID Numbers: |
LP0133-1528 2021-003543-16 ( EudraCT Number ) |
| First Posted: | February 28, 2022 Key Record Dates |
| Last Update Posted: | April 9, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | De-identified IPD can be made available to researchers in a closed environment for a specified period of time. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) |
| Time Frame: | Data is available to request after results of the trial are available on leopharmatrials.com |
| Access Criteria: | Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement. |
| URL: | http://leopharmatrials.com/for-professionals |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Eczema Dermatitis Skin Diseases Skin Diseases, Eczematous |
Alitretinoin Antineoplastic Agents Dermatologic Agents |